Karim Dabbagh, Ph.D., joins as CEO, bringing leadership experience in advancing immunology and inflammation

卡里姆·达巴格（Karim Dabbagh）博士出任首席执行官，带来在推动免疫学与炎症领域发展的领导经验

therapies through clinical trials; Rich Murray, Ph.D., former interim CEO, remains on the Board of Directors

通过临床试验推进疗法；前临时首席执行官里奇·默里（Rich Murray）博士继续担任董事会成员

Dualitas announces the nomination of DTX-102 as its lead development candidate, a bispecific antibody powered by a novel immune proximity engager mechanism, for the treatment of rheumatoid arthritis; clinical studies are anticipated to begin in 2027

Dualitas宣布提名DTX-102为其首要开发候选药物，这是一种基于新型免疫邻近结合机制的双特异性抗体，用于治疗类风湿性关节炎；预计临床试验将于2027年启动。

Dualitas announces two additional preclinical programs – enabled by its proprietary proximity engager – across large population indications including allergy, dermatology and gastrointestinal diseases

Dualitas宣布新增两项临床前项目，这些项目由其专有的邻近结合剂赋能，涵盖过敏、皮肤病学和胃肠道疾病等大人群适应症。

SOUTH SAN FRANCISCO, Calif.

加利福尼亚州南旧金山

,

，

June 8, 2026

2026年6月8日

/PRNewswire/ --

/美通社/ --

Dualitas Therapeutics, Inc.

Dualitas Therapeutics, Inc.

, a biotechnology company developing next-generation bispecific antibody therapies for immunology and inflammation ('I&I') indications, has appointed Karim Dabbagh, Ph.D., as chief executive officer to lead the company as it advances its lead development candidate, DTX-102, a bispecific antibody incorporating Dualitas' immune proximity engager, for autoimmune indications including rheumatoid arthritis.

一家致力于为免疫学与炎症（I&I）适应症开发下一代双特异性抗体疗法的生物技术公司已任命 Karim Dabbagh 博士为首席执行官，以领导公司推进其领先研发候选药物 DTX-102。DTX-102 是一种双特异性抗体，整合了 Dualitas 的免疫近端接合器技术，适用于包括类风湿性关节炎在内的自身免疫性适应症。

IND-enabling studies have begun for DTX-102 and it is anticipated to enter the clinic in 2027..

DTX-102 的 IND enabling 研究已启动，预计将于 2027 年进入临床试验阶段。

Continue Reading

继续阅读

Karim Dabbagh, Ph.D.

卡里姆·达巴格，博士

Appointment of Karim Dabbagh as Chief Executive Officer

任命卡里姆·达巴格为首席执行官

'This is a pivotal time for Dualitas, as we begin advancing the first of our differentiated bispecific antibody therapies for immune and inflammatory diseases into the clinic next year,' Dabbagh said. 'Our unique proximity engager technology with I&I applications has the potential to set a new standard in efficacy for millions of patients who are underserved by existing treatments.'.

“对于Dualitas而言，这是一个关键时刻，因为我们将于明年开始将首个针对免疫和炎症疾病的差异化双特异性抗体疗法推进至临床试验阶段，”Dabbagh表示。“我们拥有独特邻近结合技术（proximity engager technology）且在免疫与炎症领域具备应用潜力，有望为数百万现有治疗手段无法满足需求的患者树立疗效新标杆。”

Dabbagh has spent more than two decades in biotech and pharma leadership, specializing in I&I. He joins Dualitas from Silver Creek Pharmaceuticals, where he was President and CEO. Prior to that, he served as President and CEO of Second Genome, helping build the company's R&D platform and advancing its pipeline from discovery into the clinic, while also securing collaborations with Gilead Sciences and Bayer.

达巴格在生物科技和制药领导岗位深耕二十余载，专注于免疫与炎症（I&I）领域。他加入Dualitas之前，曾担任Silver Creek Pharmaceuticals的总裁兼首席执行官。在此之前，他曾任Second Genome的总裁兼首席执行官，帮助构建公司的研发平台，推动其产品线从发现阶段进入临床研究阶段，同时还促成了与吉利德科学（Gilead Sciences）和拜耳（Bayer）的合作。

Earlier in his career, he led Pfizer's immunoregulation department as well as external R&D innovation efforts in autoimmune and inflammatory diseases and previously held leadership roles in Inflammation Discovery Research at Roche..

在职业生涯早期，他曾领导辉瑞公司的免疫调节部门，并负责自身免疫性和炎症性疾病领域的外部研发创新工作；此前，他在罗氏公司担任炎症发现研究领域的领导职务。

'Karim's deep experience advancing immunology therapies from the lab to clinical trials and establishing high-value collaborations across the drug discovery ecosystem makes him exceptionally well-suited for Dualitas at this critical juncture of pipeline maturation,' said Neil Weir, Ph.D., Chairman of the Board of Directors.

“卡里姆在推动免疫学疗法从实验室走向临床试验，以及在药物研发生态系统中建立高价值合作方面拥有深厚的经验，这使他在Dualitas管线成熟的关键阶段成为 exceptionally well-suited 的人选。”董事会主席尼尔·韦尔博士表示。

'Rich Murray, Ph.D., who served as interim CEO from January 2025, has shown tremendous leadership through the Series A financing and alignment of the science to product development. We are delighted he will remain on the Board of Directors.'.

“自2025年1月起担任临时首席执行官的Rich Murray博士，在A轮融资以及将科学与产品开发对齐的过程中展现了卓越的领导力。我们很高兴他将继续留在董事会。”

DTX-102 and Dualitas 'Proximity Engager' Technology

DTX-102 与 Dualitas 的“近距接合器”技术

Dualitas' bispecific antibodies pair an internally discovered novel immune proximity engager arm with an antibody against a validated target. Unlike traditional bispecific approaches that seek incremental gains by combining two separate inhibitors, Dualitas' proximity engager pairs synergistically with diverse immune targets.

Dualitas的双特异性抗体将内部发现的新型免疫邻近结合臂与针对已验证靶点的抗体相结合。与传统的双特异性方法（通过组合两种单独的抑制剂来寻求渐进式增益）不同，Dualitas的邻近结合臂能够与多种免疫靶点产生协同作用。

This interaction drives amplified pharmacological effects that are achievable only in a bispecific format and cannot be achieved with monospecific agents. Dualitas is applying its bispecific proximity engager across multiple validated immune pathways, starting with the CD28 pathway for its DTX-102 program.

这种相互作用推动了放大的药理学效应，这些效应仅在双特异性格式下可实现，而单特异性制剂无法达成。Dualitas 正在将其双特异性邻近结合剂应用于多个经过验证的免疫通路，首先针对其 DTX-102 项目的 CD28 通路。

In vitro and in vivo preclinical studies of DTX-102 demonstrated significantly greater potency and more durable immune modulation than currently approved therapies targeting the same pathways..

DTX-102的体外和体内临床前研究显示，与目前批准的针对相同通路的治疗方案相比，其效力显著更强，免疫调节作用更持久。

In addition to DTX-102, Dualitas announces two additional programs using its proprietary proximity engager. DTX-103 is an anti-FcεRI bispecific antibody that targets the IgE pathway to treat allergic diseases like asthma, food allergy, chronic spontaneous urticaria, among others. DTX-101 targets IL-2Rβ to substantially suppress both IL-15 and IL-2 pathways and is designed for initial indications in dermatologic and gastrointestinal disease..

除了DTX-102之外，Dualitas还宣布了两个使用其专有邻近结合剂的新项目。DTX-103是一种抗FcεRI双特异性抗体，靶向IgE通路，用于治疗哮喘、食物过敏、慢性自发性荨麻疹等过敏性疾病。DTX-101靶向IL-2Rβ，可显著抑制IL-15和IL-2通路，最初设计用于皮肤病和胃肠道疾病的治疗。

Dualitas' $65 million Series A financing, announced in September 2025, will fund DTX-102 into the clinic and the ongoing development of its pipeline assets.

Dualitas于2025年9月宣布的6,500万美元A轮融资，将用于推动DTX-102进入临床试验阶段，并持续推进其管线资产的开发。

About Dualitas Therapeutics

关于 Dualitas Therapeutics

Dualitas Therapeutics, Inc. is a biotechnology company pioneering next-generation bispecific antibody (BsAb) therapies for immunology and inflammation (I&I). Dualitas' portfolio, built from its DualScreen discovery engine, includes development candidate DTX-102 in rheumatoid arthritis, DTX-103 in allergic disease and DTX-101 in dermatologic and gastrointestinal autoimmune disease, alongside additional discoveries based on cell-surface proximity biology and novel co-target pairing.

Dualitas Therapeutics, Inc. 是一家生物技术公司，致力于开创用于免疫学与炎症（I&I）领域的下一代双特异性抗体（BsAb）疗法。Dualitas 的产品组合基于其 DualScreen 发现引擎构建，包括类风湿关节炎研发候选药物 DTX-102、过敏性疾病研发候选药物 DTX-103 以及皮肤科和胃肠道自身免疫性疾病研发候选药物 DTX-101，此外还有基于细胞表面邻近生物学和新型共靶点配对的其它发现成果。

While advancing its own pipeline, Dualitas offers a variety of strategic collaboration opportunities to extend the impact of its DualScreen discovery engine, ranging from existing pipeline programs to identifying de novo BsAbs to establishing programs in disease areas beyond I&I. For more information, please visit .

在推进自身产品管线的同时，Dualitas 提供了多种战略合作机会，以扩展其 DualScreen 发现引擎的影响力，合作范围涵盖现有管线项目、从头发现新型双特异性抗体（BsAbs），以及在免疫与炎症（I&I）以外的疾病领域建立新项目。欲了解更多信息，请访问 。

https://www.dualitastx.com/

https://www.dualitastx.com/

and follow us on

并在以下平台关注我们

LinkedIn

领英

.

。

SOURCE Dualitas Therapeutics

来源：Dualitas Therapeutics

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示